Skip to main content
. 2020 Aug 15;59:102941. doi: 10.1016/j.ebiom.2020.102941

Fig. 5.

Fig. 5

Inhibition of GATA-4 transcriptional activity following treatment with the small-molecule inhibitor NSC140905. a Left, representative Western blot of GATA-4 protein expression in HMC, primary Schwann cells (MOS0718, MOS0319, and MOS0318), and KT21-MG1 cells. Right, cell viability assessed by ATP assay after administration of the GATA-4 inhibitor for 24 h, compared to vehicle-treated cells (0•1% DMSO). Bottom, densitometry analysis and representative Western blot showing a decrease in Cyclin D1 expression and Rb phosphorylation levels following GATA-4 inhibition compared to control cells. b RT-qPCR analysis of the miR-497~195 cluster expression following GATA-4 inhibition, densitometry analysis and representative Western blot of Bcl2 following GATA-4 inhibition, compared to vehicle-treated cells (0•1% DMSO). Data are reported as mean ± SEM (Two-way and one-way ANOVA; NS = not significant; * = p<0•05, ** = p<0•01, *** = p<0•005). NSC140905 treatment has been performed in three independent experiments, with one replica per repeat, to ensure data consistency. We used the highest DMSO concentration (0•1% DMSO) as vehicle control in all experiments.